Literature DB >> 35320543

Evaluation of the Bactericidal Activity of Galectins.

Nourine A Kamili1, Anu Paul1, Shang-Chuen Wu1, Marcelo Dias-Baruffi2, Richard D Cummings3, Connie M Arthur1,3, Sean R Stowell4,5.   

Abstract

Over a century ago, Karl Landsteiner discovered that blood group antigens could predict the immunological outcome of red blood cell transfusion. While the discovery of ABO(H) blood group antigens revolutionized transfusion medicine, many questions remain regarding the development and regulation of naturally occurring anti-blood group antibody formation. Early studies suggested that blood group antibodies develop following stimulation by bacteria that express blood group antigens. While this may explain the development of anti-blood group antibodies in blood group-negative individuals, how blood group-positive individuals protect themselves against blood group-positive microbes remained unknown. Recent studies suggest that several members of the galectin family specifically target blood group-positive microbes, thereby providing innate immune protection against blood group antigen-positive microbes regardless of the blood group status of an individual. Importantly, subsequent studies suggest that this unique form of immunity may not be limited to blood group expressing microbes, but may reflect a more generalized form of innate immunity against molecular mimicry. As this form of antimicrobial activity represents a unique and unprecedented form of immunity, we will examine important considerations and methodological approaches that can be used when seeking to ascertain the potential antimicrobial activity of various members of the galectin family.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antimicrobial; Blood group–positive microbes; Galectin; Innate immune lectin; Molecular mimicry

Mesh:

Substances:

Year:  2022        PMID: 35320543     DOI: 10.1007/978-1-0716-2055-7_27

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  58 in total

1.  Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood.

Authors:  E P Vichinsky; A Earles; R A Johnson; M S Hoag; A Williams; B Lubin
Journal:  N Engl J Med       Date:  1990-06-07       Impact factor: 91.245

2.  Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease.

Authors:  David Narbey; Anoosha Habibi; Philippe Chadebech; Armand Mekontso-Dessap; Mehdi Khellaf; Jean-Daniel Lelièvre; Bertrand Godeau; Marc Michel; Frédéric Galactéros; Rachid Djoudi; Pablo Bartolucci; France Pirenne
Journal:  Am J Hematol       Date:  2017-10-31       Impact factor: 10.047

Review 3.  Biologic roles of the ABH and Lewis histo-blood group antigens Part I: infection and immunity.

Authors:  Christopher P Stowell; Sean R Stowell
Journal:  Vox Sang       Date:  2019-05-09       Impact factor: 2.144

Review 4.  Biologic roles of the ABH and Lewis histo-blood group antigens part II: thrombosis, cardiovascular disease and metabolism.

Authors:  Sean R Stowell; Christopher P Stowell
Journal:  Vox Sang       Date:  2019-05-14       Impact factor: 2.144

5.  Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes.

Authors:  Anoosha Habibi; Armand Mekontso-Dessap; Constance Guillaud; Marc Michel; Keyvan Razazi; Mehdi Khellaf; Btissam Chami; Dora Bachir; Claire Rieux; Giovanna Melica; Bertrand Godeau; Frédéric Galacteros; Pablo Bartolucci; France Pirenne
Journal:  Am J Hematol       Date:  2016-07-14       Impact factor: 10.047

6.  Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience.

Authors:  Jennifer B Vidler; Kate Gardner; Kenneth Amenyah; Aleksandar Mijovic; Swee L Thein
Journal:  Br J Haematol       Date:  2015-03-05       Impact factor: 6.998

7.  Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.

Authors:  Patricia E Zerra; Courtney Cox; W Hunter Baldwin; Seema R Patel; Connie M Arthur; Pete Lollar; Shannon L Meeks; Sean R Stowell
Journal:  Blood       Date:  2017-10-04       Impact factor: 22.113

Review 8.  Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management.

Authors:  Karina Yazdanbakhsh; Russell E Ware; France Noizat-Pirenne
Journal:  Blood       Date:  2012-05-04       Impact factor: 22.113

9.  Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease.

Authors:  Satheesh Chonat; Sara Graciaa; H Stella Shin; Joanna G Newton; Maa-Ohui Quarmyne; Jeanne Boudreaux; Amy Tang; Patricia E Zerra; Margo R Rollins; Cassandra D Josephson; Clark Brown; Clinton H Joiner; Ross M Fasano; Sean R Stowell
Journal:  Haematologica       Date:  2020-12-01       Impact factor: 9.941

10.  Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal.

Authors:  Swee Lay Thein; France Pirenne; Ross M Fasano; Anoosha Habibi; Pablo Bartolucci; Satheesh Chonat; Jeanne E Hendrickson; Sean R Stowell
Journal:  Haematologica       Date:  2020-02-06       Impact factor: 11.047

View more
  1 in total

1.  Innate immune Galectin-7 specifically targets microbes that decorate themselves in blood group-like antigens.

Authors:  Shang-Chuen Wu; Nourine A Kamili; Marcelo Dias-Baruffi; Cassandra D Josephson; Matthew F Rathgeber; Melissa Y Yeung; William J Lane; Jianmei Wang; Hau-Ming Jan; Seth Rakoff-Nahoum; Richard D Cummings; Sean R Stowell; Connie M Arthur
Journal:  iScience       Date:  2022-05-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.